ClinicalTrials.gg
TerminatedNCT06073834LUNG-I3Updated Oct 30, 2026

LUNG INFECTION IN ICU (LUNG-I3)

An observational study in VAP - Ventilator Associated Pneumonia, sponsored by BioMérieux. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by BioMérieux · Observational

How we know

Why this study was terminated
Low recruitment
Updated Oct 30, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
7
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 80 studies in Pneumonia, Ventilator-Associated with a site in France — 20 open to participants now, 22 under way, 3 of them phase 3. Pneumonia, Ventilator-Associated · France.

Enrollment
32nd of 33
7 · median 268
Started
2023
with 7 others
Observational
33 of 80
9 open now
Registered
64th of 80
by date

Among the 80 studies in Pneumonia, Ventilator-Associated with a site in France, this one is the 32nd largest by enrollment of the 33 observational ones that give a count, is one of 8 that started in 2023, is one of 33 observational ones, and was the 64th registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

20 of the 80 studies in Pneumonia, Ventilator-Associated with a site in France are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Pneumonia, Ventilator-Associated with a site in France, or all of them as a file.
02

Study summary

objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils

03

Conditions studied

  • VAP - Ventilator Associated Pneumonia

Keywords

  • VAP - Ventilator Associated Pneumonia
  • Sepsis
  • Lung Infection
  • Broncho-alveolar Lavage
  • ICU
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

ICU Adult patients hospitalized and managed for septic shock or severe trauma (including severe burn) and undergoing mechanical ventilation (within 24h of admission) with an expected length upper than 3 days.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All the following criteria

  • Age 18 years or greater
  • Severe ICU patients hospitalized for one of the above diseases:

    • Septic shock (requirement of vasopressor to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia) caused either by pneumonia (n=20) or another source n=20)
    • Severe trauma (level I and II), Injury Severity Score ≥ 25 OR
    • Burn with TBSA over 20%
  • NAD > 0.1 µg/kg/min
  • At least 2 SOFA criteria ≥ 2 points

Exclusion criteria

Exclusion Criteria:

  • Aspiration pneumonia
  • Unable to obtain a valid and written consent from a patient or their legally authorized representative in accordance with the local regulatory instances (this includes in FR: Person not affiliated to a health insurance scheme, or not a beneficiary of such a scheme. Persons who are the subject of a legal protection order. Person with restricted freedom following a legal or administrative decision and a person admitted without their consent pursuant to Articles L.3212-1 and 3213-1, which are not included in Article L.1121-8 of the French Public Health Code.)
  • Smoke inhalation in burn patients
  • Participation in an intervention study
  • Pregnant or breastfeeding women
  • patients, defined as

    • patients with solid tumors with chemotherapy in the last 3 months or a progressive disease
    • hematologic
    • solid organ transplantation
    • infection with or without AIDS
    • treatment with (> 3 months at any dosage or ≥ 1 mg/kg prednisone equivalent per day for > 7 day)
    • treatment with other immunosuppressive drugs.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
7 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. immune cells patterns in VAP

    The primary endpoint will be to describe and compare the distribution of immune cells within the lung and the blood before VAP diagnosis (VAP prediction) and at the time of VAP diagnosis.

    Time frame: before and at time of VAP diagnosis

07

Study locations

1 site
  • Hopital Edouard Herriot
    Lyon, 69003, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2023 to primary completion in Apr 2025, 16 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Apr 2026 → Apr 2025 and completion Jun 2027 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2023
First posted
Oct 10, 2023
StartActual
Dec 5, 2023
Primary completionActual
Apr 24, 2025was Apr 2026
CompletionActual
Jun 25, 2026was Jun 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Low recruitment
changed Oct 30, 2026
Primary completion
Apr 2026→Apr 24, 2025 (actual)
Oct 30, 2026
Study completion
Jun 2027→Jun 25, 2026 (actual)
Oct 30, 2026
Enrollment
68 (estimated)→7 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Recruiting→Terminated
    Why stopped Low recruitment
    Primary completion Apr 2026→Apr 24, 2025 (now actual)
    Study completion Jun 2027→Jun 25, 2026 (now actual)
    Enrollment 68 (estimated)→7 (actual)
    + 6 other changes: identifiers, verification date, oversight details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06073834
Lead sponsor
BioMérieux
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Dec 5, 2023
Primary completion
Apr 24, 2025
Completion
Jun 25, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion